What were the specific clinical and CV risk profiles of the patients studied in LEADER? And how will this help us identify patients who might benefit from liraglutide?

What were the specific clinical and CV risk profiles of the patients studied in LEADER? And how will this help us identify patients who might benefit from liraglutide?

What were the specific clinical and CV risk profiles of the patients studied in LEADER? And how will this help us identify patients who might benefit from liraglutide?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Luc Van Gaal, MD

Luc Van Gaal, MD

Professor of Medicine
Department of Endocrinology, Diabetology and Metabolism
Antwerp University Hospital
Antwerp, Belgium